Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis

Research output: Contribution to journal › Article › Scientific › peer-review

53 Citations (Scopus)

Original language	English
Pages (from-to)	340-351
Journal	Journal of Medical Economics
Volume	15
Issue number	2
Publication status	Published - 2012
Publication type	A1 Journal article-refereed

Access to Document

@article{41ab4a3ae392489c900b4bdc9d2d690b,

title = "Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis",

author = "EJ Soini and TA Hallinen and K Puolakka and V Vihervaara and MJ Kauppi",

year = "2012",

language = "English",

volume = "15",

pages = "340--351",

number = "2",

}

TY - JOUR

T1 - Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis

AU - Soini, EJ

AU - Hallinen, TA

AU - Puolakka, K

AU - Vihervaara, V

AU - Kauppi, MJ

PY - 2012

Y1 - 2012

M3 - Article

SN - 1369-6998

VL - 15

SP - 340

EP - 351

JO - Journal of Medical Economics

JF - Journal of Medical Economics

IS - 2

ER -